FET PET in Neuro-oncology and in Evaluation of Treatment Response

Vincent Dunet; John O Prior

doi:10.1016/j.cpet.2012.09.005

FET PET in Neuro-oncology and in Evaluation of Treatment Response

PET Clin. 2013 Apr;8(2):147-62. doi: 10.1016/j.cpet.2012.09.005. Epub 2012 Oct 23.

Authors

Vincent Dunet¹, John O Prior²

Affiliations

¹ Department of Nuclear Medicine, Lausanne University Hospital, Rue du Bugnon 46, Lausanne 1011, Switzerland; Department of Radiology, Lausanne University Hospital, Rue du Bugnon 46, Lausanne 1011, Switzerland.
² Department of Nuclear Medicine, Lausanne University Hospital, Rue du Bugnon 46, Lausanne 1011, Switzerland. Electronic address: [email protected].

PMID: 27157945
DOI: 10.1016/j.cpet.2012.09.005

Abstract

Morphologic magnetic resonance imaging is the mainstay in the diagnosis and follow-up of primary brain tumor. However, it has limited ability to differentiate tumor from edema, necrosis, or fibrosis. PET with (18)F-fluoro-ethyl-tyrosine (FET) is a promising and complementary diagnostic and prognostic tool to probe tumor biology in vivo. This article presents the tracer biology and uptake mechanism, the imaging protocol and quantitative image analysis, common pitfalls and variants, and the main indications for FET PET. Finally, a summary on what the referring physician needs to know about FET PET is presented.